# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

**Single Technology Appraisal**

**Ipilimumab for previously treated unresectable malignant melanoma**

## Matrix of consultees and commentators

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturers/sponsors</strong></td>
<td>General</td>
</tr>
<tr>
<td>• Bristol-Myers Squibb (ipilimumab)</td>
<td>• Board of Community Health Councils in Wales</td>
</tr>
<tr>
<td><strong>Patient/carer groups</strong></td>
<td>• British National Formulary</td>
</tr>
<tr>
<td>• Action for Sick Children</td>
<td>• Care Quality Commission</td>
</tr>
<tr>
<td>• Afiya Trust</td>
<td>• Department of Health, Social Services and Public Safety for Northern Ireland</td>
</tr>
<tr>
<td>• Association for Children with Life Threatening or Terminal Conditions</td>
<td>• Medicines and Healthcare products Regulatory Agency</td>
</tr>
<tr>
<td>• Black Health Agency</td>
<td>• National Association of Primary Care</td>
</tr>
<tr>
<td>• Cancer 52</td>
<td>• NHS Alliance</td>
</tr>
<tr>
<td>• Cancer Black Care</td>
<td>• NHS Commercial Medicines Unit</td>
</tr>
<tr>
<td>• Cancer Equality</td>
<td>• NHS Confederation</td>
</tr>
<tr>
<td>• CANCERactive</td>
<td>• NHS Quality Improvement Scotland</td>
</tr>
<tr>
<td>• Chinese National Healthy Living Centre</td>
<td>• Public Health Wales NHS</td>
</tr>
<tr>
<td>• CLIC Sargent</td>
<td>• Scottish Medicines Consortium</td>
</tr>
<tr>
<td>• Counsel and Care</td>
<td></td>
</tr>
<tr>
<td>• Equalities National Council</td>
<td></td>
</tr>
<tr>
<td>• Helen Rollason Heal Cancer Charity</td>
<td></td>
</tr>
<tr>
<td>• Help Adolescents with Cancer</td>
<td></td>
</tr>
<tr>
<td>• Macmillan Cancer Support</td>
<td></td>
</tr>
<tr>
<td>• Maggie’s Centres</td>
<td></td>
</tr>
<tr>
<td>• Marie Curie Cancer Care</td>
<td></td>
</tr>
<tr>
<td>• Muslim Council of Britain</td>
<td></td>
</tr>
<tr>
<td>• Muslim Health Network</td>
<td></td>
</tr>
<tr>
<td>• National Alliance of Childhood Cancer Parent Organisations</td>
<td></td>
</tr>
<tr>
<td>• National Children’s Bureau</td>
<td></td>
</tr>
<tr>
<td>• National Council for Palliative Care</td>
<td></td>
</tr>
<tr>
<td>• NCH – The Children’s Charity</td>
<td></td>
</tr>
<tr>
<td>• Rarer Cancers Foundation</td>
<td></td>
</tr>
<tr>
<td>• Skinin - Karen Clifford Skin Cancer Charity</td>
<td></td>
</tr>
</tbody>
</table>

**Comparator manufacturer(s)**

- None

**Relevant research groups**

- British Society for Dermatological Surgery
- Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham
- Institute of Cancer Research
- MRC Clinical Trials Unit
- Melanoma Study Group
- Myfanwy Townsend Melanoma Research Fund
- National Cancer Research Institute
- National Cancer Research Network

---

National Institute for Health and Clinical Excellence
Consultation on the draft scope and provisional matrix for the appraisal of ipilimumab for previously treated malignant melanoma

Issue date: Feb 2011
### Consultees

- Skin Care Campaign
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sue Ryder Care
- Teenage Cancer Trust
- Tenovus
- Well Child

### Professional groups

- Association of Cancer Physicians
- British Association for Services to the Elderly
- British Association of Dermatologists
- British Dermatological Nursing Group
- British Geriatrics Society
- British Institute for Radiologists
- British Oncological Association (BOA)
- British Psychosocial Oncology Society
- British Skin Foundation
- Cancer Networks Pharmacists Forum
- Cancer Research UK
- National Pharmacy Association
- Primary Care Dermatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians, Medical Oncology Joint Special Committee
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

### Commentators (no right to submit or appeal)

- Policy Research Institute on Ageing and Ethnicity
- Research Institute of the Care of Older People
- Skin Cancer Research Fund
- Skin Research Centre
- Skin Treatment & Research Trust

### Evidence Review Group

- NHS Centre for Reviews & Dissemination and Centre for Health Economics - York
- National Institute for Health Research Health Technology Assessment Programme

### Associated Guideline Groups

- National Collaborating Centre for Cancer

### Associated Public Health Groups

- None

---

National Institute for Health and Clinical Excellence
Consultation on the draft scope and provisional matrix for the appraisal of ipilimumab for previously treated malignant melanoma

Issue date: Feb 2011
NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**
Appendix B

Definitions:

Consultees
Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement\(^1\), respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators
Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)
An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

\(^1\) Non manufacturer consultees are invited to submit statements relevant to the group they are representing.